- Home
- COEP vs TPST Comparison
COEP vs TPST Comparison
Compare COEP & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- TPST
- Stock Information
- Founded
- COEP 2017
- TPST 2011
- Country
- COEP United States
- TPST United States
- Employees
- COEP N/A
- TPST N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- TPST Health Care
- Exchange
- COEP Nasdaq
- TPST Nasdaq
- Market Cap
- COEP 27.4M
- TPST 33.0M
- IPO Year
- COEP N/A
- TPST N/A
- Fundamental
- Price
- COEP $9.81
- TPST $6.85
- Analyst Decision
- COEP
- TPST Hold
- Analyst Count
- COEP 0
- TPST 3
- Target Price
- COEP N/A
- TPST $30.00
- AVG Volume (30 Days)
- COEP 37.8K
- TPST 87.0K
- Earning Date
- COEP 08-15-2025
- TPST 08-07-2025
- Dividend Yield
- COEP N/A
- TPST N/A
- EPS Growth
- COEP N/A
- TPST N/A
- EPS
- COEP N/A
- TPST N/A
- Revenue
- COEP $62,874.00
- TPST N/A
- Revenue This Year
- COEP N/A
- TPST N/A
- Revenue Next Year
- COEP N/A
- TPST N/A
- P/E Ratio
- COEP N/A
- TPST N/A
- Revenue Growth
- COEP N/A
- TPST N/A
- 52 Week Low
- COEP $2.31
- TPST $5.35
- 52 Week High
- COEP $13.70
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- COEP 65.80
- TPST 47.98
- Support Level
- COEP $7.25
- TPST $6.88
- Resistance Level
- COEP $9.90
- TPST $7.64
- Average True Range (ATR)
- COEP 0.57
- TPST 0.26
- MACD
- COEP 0.30
- TPST -0.01
- Stochastic Oscillator
- COEP 100.00
- TPST 29.25
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.